Amiodarone is not automatically necessary when you have a pacemaker, and the two are not a package deal. A pacemaker keeps your heart rate from dropping too low; amiodarone is a powerful antiarrhythmic drug that controls abnormal fast rhythms. Whether you need both depends entirely on why your pacemaker was placed, what rhythm problems remain, and whether alternative treatments can handle the job with fewer side effects. In many cases, once a pacemaker is implanted, amiodarone can be reduced or stopped entirely.
Why the Two Often End Up Together
The reason this question comes up so often is that amiodarone and pacemakers tend to land in the same patients. One of the most common scenarios is tachycardia-bradycardia syndrome, a condition where the heart alternates between racing and beating dangerously slowly. The fast episodes are frequently atrial fibrillation, and the slow episodes can cause dizziness or fainting. Treating the fast rhythm with drugs like amiodarone can make the slow episodes worse, and that is exactly the dilemma that leads to a pacemaker. In this situation, the pacemaker provides a safety net for the slow rates, which then allows doctors to prescribe rate-controlling or rhythm-controlling drugs more aggressively without worrying about the heart slowing too much.1Korean Journal of Anesthesiology. Tachycardia-bradycardia syndrome in a patient with atrial fibrillation: a case report
Another common scenario involves implantable cardioverter-defibrillators, which are specialized pacemakers that can also deliver shocks to stop dangerous fast rhythms from the lower chambers of the heart. Many people with ICDs receive amiodarone specifically to reduce the number of shocks they experience. Without an antiarrhythmic drug, some ICD patients get shocked repeatedly, which is painful and distressing. Evidence suggests amiodarone is the most effective drug for preventing both appropriate shocks (from genuinely dangerous rhythms) and inappropriate shocks (from rhythms the device misinterprets as dangerous).2PubMed Central. Antiarrhythmic Drug Therapy to Avoid Implantable Cardioverter Defibrillator Shocks
So the relationship works in both directions. Sometimes the pacemaker enables amiodarone use by protecting against its tendency to slow the heart. Other times, amiodarone supports the device by keeping arrhythmias manageable. But neither device nor drug inherently requires the other.
When Amiodarone Itself Creates the Need for a Pacemaker
Here is the irony that catches many patients off guard: amiodarone can slow the heart so much that it creates the very problem a pacemaker is designed to fix. In a study of elderly patients with atrial fibrillation and prior heart attacks, amiodarone use was associated with roughly double the odds of needing a permanent pacemaker. The effect was even more pronounced in women, who had nearly four times the odds of requiring pacemaker implantation compared to those not taking amiodarone.3PubMed. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction
The risk is dose-dependent. A study tracking patients on amiodarone found the overall incidence of pacemaker insertion was about 2% per person-year, but that jumped to roughly 5% per person-year during the first 90 days of treatment, when loading doses are typically highest. Patients taking more than 200 mg daily had about three times the risk of needing a pacemaker in those early months compared to those on lower doses. Higher cumulative doses over time also carried greater risk.4PubMed. Effect of amiodarone dose on the risk of permanent pacemaker insertion
This means that if you already have a pacemaker and your doctor wants to stop amiodarone, the pacemaker may have been placed partly because of the drug in the first place. In some of those cases, stopping amiodarone might restore a heart rate fast enough that the pacemaker rarely or never needs to kick in. In other cases, the underlying conduction disease was already there and amiodarone just tipped it over the edge. Sorting out which scenario applies to you requires careful monitoring.
Can a Pacemaker Replace Amiodarone for Rhythm Control?
Modern pacemakers are not just passive metronomes. Some have built-in algorithms designed to suppress atrial fibrillation by pacing the upper chambers slightly faster than the heart’s natural rate, reducing the pauses and irregularities that can trigger arrhythmia episodes. In the Atrial Dynamic Overdrive Pacing Trial, one such algorithm cut the burden of symptomatic atrial fibrillation by about 25% compared to standard pacing alone.5Journal of the American College of Cardiology. A new pacemaker algorithm for the treatment of atrial fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT) Another trial found that overdrive pacing in patients with frequent drug-resistant episodes reduced the weekly number of symptomatic atrial fibrillation episodes significantly compared to standard pacing.6PubMed. Effect of right atrial overdrive pacing in the prevention of symptomatic paroxysmal atrial fibrillation
These reductions are real but modest. A 25% drop in arrhythmia burden helps, but it is not the kind of dramatic suppression that amiodarone provides when it works well. For patients whose atrial fibrillation is infrequent or mildly symptomatic, pacemaker algorithms alone might be enough. For patients with persistent, highly symptomatic arrhythmia, the algorithms are better thought of as a supplement to medication rather than a replacement for it.
The AV Node Ablation Strategy
For patients with atrial fibrillation that resists both drugs and standard procedures, there is a more aggressive option that pairs a pacemaker with ablation. In this approach, a catheter is used to deliberately destroy the electrical connection between the upper and lower chambers of the heart (the AV node), and a permanent pacemaker takes over the job of driving the lower chambers at a steady rate. The atrial fibrillation continues in the upper chambers, but the lower chambers no longer feel it, so the racing and irregularity stop.
This strategy has shown real benefits for quality of life. In one study, patients who underwent AV node ablation plus pacemaker implantation showed improvements in palpitations (reduced by about 78%), effort-related breathlessness, exercise tolerance, and chest discomfort at twelve months. All variables except easy fatigue improved significantly from baseline in the ablation-and-pacemaker group.7PubMed. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation In another study, patients with heart failure and uncontrolled atrial fibrillation who received AV node ablation plus pacemaker saw their heart’s pumping efficiency improve from about 32% to 42% within four weeks, along with better exercise capacity and quality-of-life scores.8PubMed Central. Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation
The key point here is that the ablation-and-pacemaker approach often eliminates the need for amiodarone entirely, because the pacemaker handles rhythm control on its own by overriding the chaotic signals. The trade-off is that you become permanently dependent on the pacemaker. For patients already dealing with serious side effects from amiodarone, that trade-off is frequently worth it.
Why Doctors Want to Minimize Amiodarone Use
Amiodarone is effective, but it is also one of the most toxic drugs in regular clinical use. It accumulates in tissues throughout the body, and its half-life is measured in weeks to months. The drug can damage the liver, ranging from mild enzyme elevations to full-blown liver failure. It can cause lung toxicity, including a form of pneumonia that is potentially fatal. It disrupts thyroid function in both directions, causing either an overactive or underactive thyroid. It can also deposit in the corneas and skin, causing visual disturbances and a distinctive blue-gray discoloration.9PubMed Central. Amiodarone-Induced Multi-Systemic Toxicity Involving the Liver, Lungs, Thyroid, and Eyes: A Case Report
Because of these risks, anyone on amiodarone needs regular monitoring of thyroid function, liver enzymes, lung imaging, and eye exams. The burden of this monitoring, combined with the cumulative toxicity risk, gives doctors a strong incentive to stop the drug whenever possible. If a pacemaker is managing the slow-heart-rate problem and the fast-rhythm problem has been addressed through ablation or another drug, continuing amiodarone becomes harder to justify.
In older patients especially, the risks are amplified. Amiodarone interacts with a long list of other medications, including blood thinners, cholesterol drugs, and digoxin. Older adults are more susceptible to its thyroid and lung effects, and those who already have liver or lung disease should avoid it if at all possible.10PubMed Central. Amiodarone in the aged The drug should not be used purely to control heart rate when safer alternatives exist. If your only remaining problem is a heart that occasionally goes too fast, there are simpler medications, and a pacemaker ensures those medications will not drop your rate too low.
Amiodarone and Defibrillation Thresholds in ICD Patients
If you have an ICD rather than a simple pacemaker, amiodarone creates a specific complication worth knowing about. The drug can raise the defibrillation threshold, meaning the ICD needs more energy to successfully shock the heart out of a dangerous rhythm. In animal studies, chronic oral amiodarone roughly doubled the energy required for successful defibrillation in a dose-dependent fashion, while a single intravenous dose did not have the same effect.11PubMed. The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs Whether this means ICD patients on amiodarone need routine retesting of their device is still debated among cardiologists. On the positive side, amiodarone can slow fast rhythms enough that the ICD can terminate them with painless pacing instead of a full shock, which is a meaningful benefit for the patient’s experience.
Catheter Ablation as a Path Away From Amiodarone
In recent years, catheter ablation for atrial fibrillation has become an increasingly common way to address the rhythm problem directly, potentially making both amiodarone and some pacemaker-related strategies unnecessary. Unlike the AV node ablation described earlier (which destroys the electrical bridge and requires permanent pacing), pulmonary vein isolation targets the spots where atrial fibrillation originates, aiming to cure or substantially reduce the arrhythmia itself.
The cost picture is informative. A cost-effectiveness analysis found that catheter ablation for atrial fibrillation cost about $26,600 over five years compared to roughly $19,900 for antiarrhythmic drug therapy, but the ablation group gained slightly more quality-adjusted life years. The incremental cost worked out to about $51,400 per quality-adjusted life year gained, which is within the range health systems generally consider acceptable.12PubMed Central. Cost-Effectiveness of Radiofrequency Catheter Ablation Compared with Antiarrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation For ventricular tachycardia in patients with ICDs who are getting frequent shocks, ablation versus amiodarone showed an even more favorable cost-effectiveness ratio of about $21,000 per quality-adjusted life year.13PubMed. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia
For many patients, ablation offers the possibility of getting off amiodarone entirely. If the ablation succeeds at eliminating atrial fibrillation, the original reason for the drug may disappear. The pacemaker stays, since it was implanted for a structural reason, but the medication burden lightens considerably.
Newer Drugs and the Evolving Landscape
Amiodarone has been the workhorse antiarrhythmic for decades partly because alternatives were limited or less effective. That is changing. For acute conversion of atrial fibrillation back to normal rhythm, vernakalant has shown dramatically faster results. In one trial, over half of patients treated with vernakalant converted to normal rhythm within 90 minutes, with a median conversion time of just 11 minutes in responders, compared to only about 5% of patients given amiodarone in the same timeframe.14Journal of the American College of Cardiology. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation
Vernakalant is used intravenously for recent-onset episodes rather than as a daily maintenance drug, so it does not directly replace amiodarone’s long-term role. But it illustrates a broader trend: the toolkit for managing heart rhythm is expanding, which means fewer patients need to default to amiodarone simply because nothing else works well enough. For patients who have a pacemaker providing their rate safety net, the growing menu of alternatives makes it increasingly possible to avoid amiodarone’s toxicity profile.
The Specific Role of Cardiac Resynchronization Devices
Some patients have a more specialized device called a cardiac resynchronization therapy pacemaker, or CRT, which coordinates the timing of the heart’s lower chambers to improve pumping efficiency in heart failure. For people with both heart failure and permanent atrial fibrillation, the situation is more complicated. Observational studies and a randomized trial suggest CRT can help these patients, but the benefits appear to depend on achieving a very high percentage of paced beats. In practice, that often means combining CRT with AV node ablation to ensure the device controls the rhythm rather than competing with the chaotic atrial fibrillation signals.15Current Opinion in Cardiology. Cardiac resynchronization therapy in the setting of permanent atrial fibrillation and heart failure
In this context, amiodarone might be used as a bridge to reduce atrial fibrillation burden enough for CRT to work, or it might be eliminated entirely once AV node ablation ensures the device has full control. The decision hinges on how well the device is capturing the heart’s rhythm on its own. If biventricular pacing is happening during nearly every heartbeat, amiodarone is adding little. If atrial fibrillation is overriding the device’s timing, either amiodarone or ablation becomes necessary to let CRT do its job.
Practical Questions for Your Own Situation
If you have a pacemaker and are on amiodarone, the question of whether to continue the drug is worth raising with your cardiologist at every visit. The answer depends on a few things your doctor can assess: whether your underlying heart rhythm problem is still active, whether your pacemaker records show frequent arrhythmia episodes, and whether the original reason for amiodarone still exists or has been resolved by the device or by an ablation procedure.
Stopping amiodarone is not something to do on your own. The drug leaves the body slowly over weeks to months, and arrhythmias can return during or after that washout period. Your pacemaker can provide some protection against dangerously slow rates during this transition, but it cannot prevent fast arrhythmias from returning. Tapering under medical supervision, with device checks along the way, is the safe approach.
For patients who were placed on amiodarone before the pacemaker went in, and whose pacemaker was implanted at least partly because amiodarone slowed their heart too much, there is a reasonable chance the drug can eventually be stopped or the dose reduced. For patients whose pacemaker was placed for a separate reason and who take amiodarone for a rhythm problem the device cannot address, the drug may need to continue unless ablation or an alternative medication can take over. Each case is genuinely individual, and the device’s stored data, which records every arrhythmia episode, gives your doctor real evidence to base the decision on rather than guessing.